VistaGen Therapeutics (NASDAQ:VTGN) Releases Quarterly Earnings Results, Misses Expectations By $0.03 EPS

VistaGen Therapeutics (NASDAQ:VTGN) released its earnings results on Monday. The company reported ($0.37) earnings per share for the quarter, missing the consensus estimate of ($0.34) by ($0.03), FiscalAI reports. The firm had revenue of $0.38 million for the quarter, compared to the consensus estimate of $0.40 million.

VistaGen Therapeutics Trading Down 0.6%

VTGN stock traded down $0.00 on Monday, hitting $0.57. 1,022,848 shares of the company’s stock traded hands, compared to its average volume of 895,989. VistaGen Therapeutics has a 1-year low of $0.43 and a 1-year high of $5.14. The stock has a market cap of $22.70 million, a price-to-earnings ratio of -0.30 and a beta of 0.31. The stock has a fifty day moving average of $0.60 and a 200-day moving average of $1.03.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on the stock. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of VistaGen Therapeutics in a research report on Wednesday, June 3rd. Wall Street Zen lowered shares of VistaGen Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, March 21st. Four equities research analysts have rated the stock with a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Reduce” and an average price target of $0.95.

Institutional Trading of VistaGen Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in VTGN. Luminus Management LLC acquired a new stake in VistaGen Therapeutics during the fourth quarter valued at approximately $232,000. Two Sigma Investments LP lifted its stake in VistaGen Therapeutics by 223.5% during the third quarter. Two Sigma Investments LP now owns 289,409 shares of the company’s stock valued at $1,027,000 after purchasing an additional 199,958 shares during the last quarter. Millennium Management LLC lifted its stake in VistaGen Therapeutics by 853.0% during the fourth quarter. Millennium Management LLC now owns 197,045 shares of the company’s stock valued at $130,000 after purchasing an additional 176,369 shares during the last quarter. OMERS ADMINISTRATION Corp acquired a new stake in VistaGen Therapeutics during the fourth quarter valued at approximately $68,000. Finally, Jane Street Group LLC acquired a new stake in shares of VistaGen Therapeutics during the second quarter valued at approximately $190,000. 78.39% of the stock is owned by institutional investors and hedge funds.

VistaGen Therapeutics Company Profile

VistaGen Therapeutics, Inc (NASDAQ:VTGN) is a clinical-stage biopharmaceutical company dedicated to the discovery and development of next-generation medicines for central nervous system disorders. Incorporated in Delaware in 1998 and headquartered in South San Francisco, California, VistaGen applies advanced human pluripotent stem cell technologies to accelerate drug candidate validation and optimization. The company’s core focus is on addressing unmet medical needs in major depressive disorder, neuropathic pain and dermatological conditions.

The company’s lead candidate, AV-101, is an oral prodrug designed to modulate glutamatergic neurotransmission via the N-methyl-D-aspartate (NMDA) receptor pathway, with clinical programs targeting major depressive disorder and neuropathic pain.